Personalized cancer medicine for non-small cell lung cancer

非小细胞肺癌的个体化癌症药物

• 批准号: 22590864
• 负责人: ISOBE Takeshi
• 金额: $ 2.91万
• 依托单位: Shimane University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590864/
• 关键词: 非閉塞性肺疾患; 肺線維症; 呼吸器感染症; 肺癌; 個別化治療; 非閉塞性肺疾患癌

We developed a reliable, reproducible, and simple orthotopic model for human lung cancer cell line using nude mice, multiple models with different biologic and clinical phenotypes may allow a better understanding of the behavior and treatment effects. We also showed correlation of the biomarker expression between biopsy specimens and surgical specimens assessed by IHC. Finally, we conducted a phase I/II clinical study of combination chemotherapy with EGFR-tyrosine kinase inhibitor and cytotoxic agent for recurrent lung cancer.These results lead to individualized chemotherapy and benefit patients with advanced non-small-cell lung cancer.

我们建立了一个可靠的、可重复的、简单的人肺癌细胞裸鼠原位模型，具有不同生物学和临床表型的多个模型可以更好地理解行为和治疗效果。我们还显示了通过IHC评估的活检标本和手术标本之间的生物标志物表达的相关性。最后，我们进行了EGFR-酪氨酸激酶抑制剂联合细胞毒药物治疗复发性肺癌的I/II期临床研究，这些结果导致了个体化化疗，使晚期非小细胞肺癌患者受益。

项目成果

Comparison of biomarker expression between biopsy and surgical specimens of non-small-cell lung cancer. Assessement by immunohistochemical staining.

非小细胞肺癌活检和手术标本之间生物标志物表达的比较。

• 发表时间: 2012
• 作者: Okimoto T;Tsubata Y;Sutani A;Fuchita H;Koba N;Nishikawa E;Hotta T;Okimoto T;Iwamoto S;Karino F;Miura K;Tada M;Suzuki T;Honda T;Hamaguchi S;Ohe M;Sutani A;Kuraki T;Isobe T
• 通讯作者: Isobe T

Effect of erlotinib on the pharmacokinetics of irinotecan and its metabolites in an animal model: a drug-drug interaction study

动物模型中厄洛替尼对伊立替康及其代谢物药代动力学的影响：药物相互作用研究

• 发表时间: 2013
• 作者: Sanematsu E;Isobe T
• 通讯作者: Isobe T